Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.

Shenzhen Stock Exchange 300357.SZ

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. Capital Expenditure for the year ending December 31, 2023: USD -29.46 M

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. Capital Expenditure is USD -29.46 M for the year ending December 31, 2023, a -7.72% change year over year. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. Capital Expenditure for the year ending December 31, 2022 was USD -27.35 M, a -42.26% change year over year.
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. Capital Expenditure for the year ending December 31, 2021 was USD -19.23 M, a -78.87% change year over year.
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. Capital Expenditure for the year ending December 31, 2020 was USD -10.75 M, a 25.02% change year over year.
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. Capital Expenditure for the year ending December 31, 2019 was USD -14.34 M, a -70.72% change year over year.

Key data

Date	Capital Expenditure	Free Cash Flow	Depreciation And Amortization	Deferred Income Tax

Shenzhen Stock Exchange: 300357.SZ

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.

CEO	Mr. Gengxi Hu Ph.D.
IPO Date	Jan. 21, 2014
Location	China
Headquarters	No. 636, Zhiyuan North Road
Employees	1,709
Sector	Healthcare
Industries Biotechnology Cosmetics Personal Care Pharmaceuticals Vaccines

Description

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd., a biopharmaceutical company, researches, develops, produces, and sells pharmaceutical products for the diagnosis and treatment of allergic diseases in China and internationally. It also offers skin care and stem cells series. The company is headquartered in Huzhou, China.

Key trends

Past 5 years